RT Journal Article
SR Electronic
T1 Antimicrobial agents for the treatment of enteric fever chronic carriage: A systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.09.21266081
DO 10.1101/2021.11.09.21266081
A1 McCann, N
A1 Scott, P
A1 Parry, CM
A1 Brown, M
YR 2021
UL http://medrxiv.org/content/early/2021/11/09/2021.11.09.21266081.abstract
AB Background Chronic carriage of S. Typhi or S. Paratyphi is an important source of enteric fever transmission. Existing guidance and treatment options for this condition are limited. This systematic review aims to assess the evidence concerning the efficacy of different antimicrobials in treating enteric fever chronic carriage.Methods We searched major bibliographic databases using relevant keywords between 1946 and September 2021. We included all interventional studies that included patients with confirmed enteric fever chronic carriage and deployed an antimicrobial that remains in clinical practice today. Case reports and case series of under 10 patients were excluded. Two reviewers screened abstracts, selected articles for final inclusion and quality-assessed the included studies for risk of bias. Extracted data was analysed, with pooling of data and eradication rates for each antimicrobial calculated. As only one randomised controlled trial was identified no meta-analysis was performed.Results Of the 593 papers identified by the initial search, a total of eight studies met the inclusion criteria and were included in the systematic review. Evidence was identified for the use of fluoroquinolones and amoxicillin/ampicillin in the treatment for enteric fever chronic carriage. Fluoroquinolones were superior to amoxicillin/ampicillin with 92% of patients eradicated after one antimicrobial course compared to 68% (p = 0.02). The quality of included studies was poor, and all were carried out before 1990.Conclusion This review identified fluoroquinolones and amoxicillin as treatment options for enteric fever chronic carriage, with fluoroquinolones the more effective option. However, this evidence pre-dates rises in antimicrobial resistance in enteric fever and therefore the significance of these findings to today’s practice is unclear. Further research is needed to investigate whether these antimicrobials remain appropriate treatment options or whether alternative interventions are more effective.Author summary There are more than 14 million cases of enteric fever every year globally. The rise of antimicrobial resistance against S. Typhi and S. Paratyphi, the pathogens causing enteric fever, has led to limited treatment options against this condition. Mechanisms to prevent infection are therefore becoming increasingly important. Public health measures and, more recently, the development and rollout of the typhoid conjugate vaccine, are going some way towards reducing transmission of this condition but identification and treatment of enteric fever chronic carriers has been neglected.S. Typhi and S. Paratyphi are restricted to human hosts and transmitted via the ingestion of contaminated food or water. Chronic carriers, those who asymptomatically excrete the pathogens in their stool following infection, play an important role in maintaining the reservoir of infection within humans. Identification and treatment of these carriers will be vital in further reducing transmission of enteric fever and ultimately eliminating this condition.Here we review the evidence for antimicrobials in treating enteric fever chronic carriage. We identify evidence for fluoroquinolones and amoxicillin as treatment strategies but highlight large gaps in the literature on this subject, including a lack of evidence in the antimicrobial-resistant era of enteric fever.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data which can be obtained from already published research papers available online as referencedI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript